PERSPECTIVE THERAPEUTICS, INC. Loss Contingency, Damages Sought, Value
PERSPECTIVE THERAPEUTICS, INC. (CATX) reported Loss Contingency, Damages Sought, Value of $3.54 million for the 1-month period ending 2016-09-23, per its 10-Q filed 2017-02-09.
Discontinued › Notes › Commitment and Contingencies › Loss Contingency
us-gaap:LossContingencyDamagesSoughtValue · last filed 2017-02-09
- 2016-09-23: Loss Contingency, Damages Sought, Value 1 month $3.54M.
| Period end | Loss Contingency, Damages Sought, Value 1 month |
|---|---|
| 2016-09-23 | $3.54M 10-Q · filed 2017-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |